Autoantibodies and neurodegeneration in multiple sclerosis

Laboratory Investigation

Volumn 88, Issue 8, 2008, Pages 796-807

  Vyshkina, Tamara ^a   Kalman, Bernadette ^a,b  

^a SYRACUSE VA MEDICAL CENTER   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Autoantibodies; Multiple sclerosis; Neurodegeneration

Indexed keywords

AMANTADINE; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; BETA ARRESTIN ANTIBODY; COLLAPSIN RESPONSE MEDIATED PROTEIN 5 ANTIBODY; DIZOCILPINE; DNA VACCINE; GANGLIOSIDE ANTIBODY; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; GLUTAMATE DECARBOXYLASE ANTIBODY; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR 3 ANTIBODY; GLUTAMATE RECEPTOR ANTIBODY; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; HEAT SHOCK COGNATE PROTEIN 70 ANTIBODY; HEAT SHOCK PROTEIN 70 ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MEMANTINE; MONOCLONAL ANTIBODY; MYELIN ANTIBODY; N METHYL DEXTRO ASPARTIC ACID RECEPTOR ANTIBODY; NERVE CELL ANTIBODY; NEUROFASCIN ANTIBODY; NEUROFIBRIL ANTIBODY; PROTEOSOME ANTIBODY; RIBONUCLEOPROTEIN ANTIBODY; RITUXIMAB;

ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CELLULAR IMMUNITY; COMPLEMENT DEPENDENT CYTOTOXICITY; DEMYELINATION; DISEASE ASSOCIATION; DRUG EFFECT; ENCEPHALITIS; EXCITOTOXICITY; GENE MUTATION; HUMAN; HUMORAL IMMUNITY; IMMUNE MEDIATED INJURY; LEBER HEREDITARY OPTIC NEUROPATHY; LYMPHOCYTE ACTIVATION; MOLECULAR DYNAMICS; MULTIPLE SCLEROSIS; NERVE CELL NECROSIS; NERVE DEGENERATION; NERVE FIBER DEGENERATION; NEUROTOXICITY; NONHUMAN; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT OUTCOME;

ANTIBODY FORMATION; AUTOANTIBODIES; B-LYMPHOCYTES; HUMANS; MULTIPLE SCLEROSIS; NEURODEGENERATIVE DISEASES; NEURONS; NEUROTOXICITY SYNDROMES;

EID: 48749090992     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2008.53     Document Type: Short Survey

References (112)

1. Bruck W, Stadelmann C. The spectrum of multiple sclerosis: new lessons from pathology. Curr Opin Neurol 2005;18:221-224.
2. Chitnis T. The role of CD4 T cells in the pathogenesis of multiple sclerosis. Int Rev Neurobiol 2007;79:43-72.
3. Bynoe MS, Bonorino P, Viret C. Control of experimental autoimmune encephalomyelitis by CD4+ suppressor T cells: peripheral versus in situ immunoregulation. J Neuroimmunol 2007;191:61-69.
4. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285.
5. Traboulsee A. MRI relapses have significant pathologic and clinical implications in multiple sclerosis. J Neurol Sci 2007;256(Suppl 1):S19-S22.
6. Zivadinov R, Cox JL. Neuroimaging in multiple sclerosis. Int Rev Neurobiol 2007;79:449-474.
7. Peterson JW, Bö L, Mörk S, et al. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001;50:389-400.
8. De Jager PL, Hafler DA. New therapeutic approaches for multiple sclerosis. Annu Rev Med 2007;58:417-432.
9. Sobel RA. The extracellular matrix in multiple sclerosis lesions. J Neuropathol Exp Neurol 1998;57:205-217.
10. Klawiter EC, Cross AH. B cells: no longer the nondominant arm of multiple sclerosis. Curr Neurol Neurosci Rep 2007;7:231-238.
11. Lindberg RL, Achtnichts L, Hoffmann F, et al. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol 2008;194:153-164.
12. Ghafourifar P, Mousavizadeh K, Parihar MS, et al. Mitochondria in multiple sclerosis. Front Biosci 2008;13:3116-3126.
13. Kalman B. Role of mitochondria in multiple sclerosis. Curr Neurol Neurosci Rep 2006;6:244-252.
14. Kalman B, Laitinen K, Komoly S. The involvement of mitochondria in the pathogenesis of multiple sclerosis. J Neuroimmunol 2007;188:1-12.
15. Blokhin A, Vyshkina T, Komoly S, et al. Lack of mitochondrial DNA deletions in lesions of multiple sclerosis. Neuromolecular Med 2008;Feb:20;Epub.
16. DeVries GH. Cryptic axonal antigens and axonal loss in multiple sclerosis. Neurochem Res 2004;29:1999-2006.
17. Mathey EK, Derfuss T, Storch MK, et al. Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med 2007;204:2363-2372.
18. Sadatipour BT, Greer JM, Pender MP. Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann Neurol 1998;44:980-983.
19. Kanda T, Iwasaki T, Yamawaki M, et al. Anti-GM1 antibody facilitates leakage in an in vitro blood-nerve barrier model. Neurology 2000;55:585-587.
20. Lehmann HC, Lopez PH, Zhang G, et al. Passive immunization with anti-ganglioside antibodies directly inhibits axon regeneration in an animal model. J Neurosci 2007;27:27-34.
21. Marconi S, Acler M, Lovato L, et al. Anti-GD2-like IgM autoreactivity in multiple sclerosis patients. Mult Scler 2006;12:302-308.
22. Eikelenboom MJ, Petzold A, Lazeron RH, et al. Multiple sclerosis: neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology 2003;60:219-223.
23. Bartos A, Fialová L, Soukupová J, et al. Antibodies against light neurofilaments in multiple sclerosis patients. Acta Neurol Scand 2007a;116:100-107.
24. Ehling R, Lutterotti A, Wanschitz J, et al. Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis. Mult Scler 2004;10:601-606.
25. Huizinga R, Heijmans N, Schubert P, et al. Immunization with neurofilament light protein induces spastic paresis and axonal degeneration in Biozzi ABH mice. J Neuropathol Exp Neurol 2007;66:295-304.
26. Theiss C, Napirei M, Meller K. Impairment of anterograde and retrograde neurofilament transport after anti-kinesin and anti-dynein antibody microinjection in chicken dorsal root ganglia. Eur J Cell Biol 2005;84:29-43.
27. Sudo A, Endo M, Saitoh S. Serum anti-arrestin antibody and disease activity of multiple sclerosis - a case report of 4-year-old child. No To Hattatsu 2000;32:415-419.
28. Gorczyca WA, Ejma M, Witkowska D, et al. Retinal antigens are recognized by antibodies present in sera of patients with multiple sclerosis. Ophthalmic Res 2004;36:120-123.
29. Hermitte L, Martin-Moutot N, Boucraut J, et al. Humoral immunity against glutamic acid decarboxylase and tyrosine phosphatase IA-2. J Clin Immunol 2000;20:287-293.
30. Agius MA, Kirvan CA, Schafer AL, et al. High prevalence of anti-alpha-crystallin antibodies in multiple sclerosis: correlation with severity and activity of disease. Acta Neurol Scand 1999;100:139-147.
31. Chiba S, Yokota S, Yonekura K, et al. Autoantibodies against HSP70 family proteins were detected in the cerebrospinal fluid from patients with multiple sclerosis. J Neurol Sci 2006;241:39-43.
32. Yonekura K, Yokota S, Tanaka S, et al. Prevalence of anti-heat shock protein antibodies in cerebrospinal fluids of patients with Guillain-Barré syndrome. J Neuroimmunol 2004;156:204-209.
33. Roussel V, Yi F, Jauberteau MO, et al. Prevalence and clinical significance of anti-phospholipid antibodies in multiple sclerosis: a study of 89 patients. J Autoimmun 2000;14:259-265.
34. Ferreira S, D'Cruz DP, Hughes GRV. Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand? Rheumatology (Oxford) 2005;44:434-442.
35. Lu F, Kalman B. Autoreactive IgG to intracellular proteins in sera of MS patients. J Neuroimmunol 1999;99:72-81.
36. Sueoka E, Yukitake M, Iwanaga K, et al. Autoantibodies against heterogeneous nuclear ribonucleoprotein B1 in CSF of MS patients. Ann Neurol 2004;56:778-786.
37. Mayo I, Arribas J, Villoslada P, et al. The proteasome is a major autoantigen in multiple sclerosis. Brain 2002;125:2658-2667.
38. Cepok S, Rosche B, Grummel V, et al. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 2005;128(Part 7):1667-1676.
39. Serafini B, Rosicarelli B, Franciotta D, et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 2007;204:2899-2912.
40. Bartos A, Fialová L, Soukupová J, et al. Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis. J Neurol 2007b;254:20-25.
41. Willison HJ. Basic and clinical aspects of autoimmune disorders in peripheral nerves. Acta Neurol Scand Suppl 2006;183:14-18.
42. Lily O, Palace J, Vincent A. Serum autoantibodies to cell surface determinants in multiple sclerosis: a flow cytometric study. Brain 2004;127(Part 2):269-279.
43. Huizinga R, Linington C, Amor S. Resistance is futile: antineuronal autoimmunity in multiple sclerosis. Trends Immunol 2008;29:54-60.
44. Howell OW, Palser A, Polito A, et al. Disruption of neurofascin localization reveals early changes preceding demyelination and remyelination in multiple sclerosis. Brain 2006;129(Part 12):3173-3185.
45. Maier O, Baron W, Hoekstra D. Reduced raft-association of NF155 in active MS-lesions is accompanied by the disruption of the paranodal junction. Glia 2007;55:885-895.
46. Varadi A, Johnson-Cadwell LI, Cirulli V, et al. Cytoplasmic dynein regulates the subcellular distribution of mitochondria by controlling the recruitment of the fission factor dynamin-related protein-1. J Cell Sci 2004;117(Part 19):4389-4400.
47. Rutter GA, Rizzuto R. Regulation of mitochondrial metabolism by ER Ca2+ release: an intimate connection. Trends Biochem Sci 2000;25:215-221.
48. Karbowski M, Youle RJ. Dynamics of mitochondrial morphology in healthy cells and during apoptosis. Cell Death Differ 2003;10:870-880.
49. Espay AJ, Chen R. Rigidity and spasms from autoimmune encephalomyelopathies: stiff-person syndrome. Muscle Nerve 2006;34:677-690.
50. Taplin CE, Barker JM. Autoantibodies in type 1 diabetes. Autoimmunity 2008;41:11-18.
51. Cid C, Regidor I, Alcázar A. Anti-heat shock protein 90beta antibodies are detected in patients with multiple sclerosis during remission. J Neuroimmunol 2007;184:223-226.
52. Bieber AJ, Warrington A, Pease LR, et al. Humoral autoimmunity as a mediator of CNS repair. Trends Neurosci 2001;24:S39-S44.
53. Soldan MM, Warrington AE, Bieber AJ, et al. Remyelination- promoting antibodies activate distinct Ca(2+) influx pathways in astrocytes and oligodendrocytes: relationship to the mechanism of myelin repair. Mol Cell Neurosci 2003;22:14-24.
54. DeJong BA, Smith ME. A role for complement in phagocytosis of myelin. Neurochem 1997;22:491-498.
55. Zaffaroni M. Biological indicators of the neurodegenerative phase of multiple sclerosis. Neurol Sci 2003;24(Suppl 5):S279-S282.
56. Winer JB. Guillain Barre syndrome. Mol Pathol 2001;54:381-385.
57. Shi Y, Feng Y, Kang J, et al. Critical regulation of CD4+ T cell survival and autoimmunity by beta-arrestin-1. Nat Immunol 2007;8:817-824.
58. Frederick TJ, Miller SD. Arresting autoimmunity by blocking beta-arrestin-1. Nat Immunol 2007;8:791-792.
59. Keegan M, König F, McClelland R, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005;366:579-582.
60. Hauser SL, Waubant E, Arnold DL, , et al., HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-688.
61. Lucchinetti C, Brück W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-717.
62. Owens GP, Burgoon MP, Anthony J, et al. The immunoglobulin G heavy chain repertoire in multiple sclerosis plaques is distinct from the heavy chain repertoire in peripheral blood lymphocytes. Clin Immunol 2001;98:258-263.
63. Lambracht-Washington D, O'Connor KC, Cameron EM, et al. Antigen specificity of clonally expanded and receptor edited cerebrospinal fluid B cells from patients with relapsing remitting MS. J Neuroimmunol 2007;186:164-176.
64. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 2007;61:288-299.
65. Banwell B, Krupp L, Kennedy J, et al. Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol 2007;6:773-781.
66. Dhib-Jalbut S. Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis. Neurology 2007;68(Suppl 3):S13-S21.
67. Genain CP, Cannella B, Hauser SL, et al. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999;5:170-175.
68. O'Connor KC, Appel H, Bregoli L, et al. Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein. J Immunol 2005;175:1974-1982.
69. Dutta R, Trapp BD. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 2007;68(Suppl 3):S22-S31.
70. Vaknin-Dembinsky A, Weiner HL. Relationship of immunologic abnormalities and disease stage in multiple sclerosis: implications for therapy. J Neurol Sci 2007;259:90-94.
71. Holmoy T. Immunopathogenesis of multiple sclerosis: concepts and controversies. Acta Neurol Scand Suppl 2007;187:39-45.
72. Pender MP, Greer JM. Immunology of multiple sclerosis. Curr Allergy Asthma Rep 2007;7:285-292.
73. Amor S, Giovannoni G. Antibodies to myelin oligodendrocyte glycoprotein as a biomarker in multiple sclerosis - are we there yet? Mult Scler 2007;13:1083-1085.
74. Lutterotti A, Berger T, Reindl M. Biological markers for multiple sclerosis. Curr Med Chem 2007;14:1956-1965.
75. Ravindranath MH, Muthugounder S, Saravanan TS, et al. Human antiganglioside autoantibodies: validation of ELISA. Ann NY Acad Sci 2005;1050:229-242.
76. Miller CC, Ackerley S, Brownlees J, et al. Axonal transport of neurofilaments in normal and disease states. Cell Mol Life Sci 2002;59:323-330.
77. Rao MV, Nixon RA. Defective neurofilament transport in mouse models of amyotrophic lateral sclerosis: a review. Neurochem Res 2003;28:1041-1047.
78. Forooghian F, Cheung RK, Smith WC, et al. Enolase and arrestin are novel nonmyelin autoantigens in multiple sclerosis. J Clin Immunol 2007;27:388-396.
79. Demakova EV, Korobov VP, Lemkina LM. Determination of gamma-aminobutyric acid concentration and activity of glutamate decarboxylase in blood serum of patients with multiple sclerosis. Klin Lab Diagn 2003;4:15-17.
80. Raska M, Weigl E. Heat shock proteins in autoimmune diseases. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2005;149:243-249.
81. Matute C, Domercq M, Sanchez-Gomez MV. Glutamate-mediated glial injury: mechanisms and clinical importance. Glia 2006;53:212-224.
82. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994;330:613-622.
83. Pitt D, Nagelmeier IE, Wilson HC, et al. Glutamate uptake by oligodendrocytes: implications for excitotoxicity in multiple sclerosis. Neurology 2003;61:1113-1120.
84. Vercellino M, Merola A, Piacentino C, et al. Altered glutamate reuptake in relapsing-remitting and secondary progressive multiple sclerosis cortex: correlation with microglia infiltration, demyelination, and neuronal and synaptic damage. J Neuropathol Exp Neurol 2007;66:732-739.
85. Srinivasan R, Sailasuta N, Hurd R, et al. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain 2005;128:1016-1025.
86. Stover JF, Pleines UE, Morganti-Kossmann MC, et al. Neurotransmitters in cerebrospinal fluid reflect pathological activity. Eur J Clin Invest 1997;27:1038-1043.
87. Sarchielli P, Greco L, Floridi A, et al. Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid. Arch Neurol 2003;60:1082-1088.
88. Choi DW. Glutamate neurotoxicity in cortical cell culture is calcium dependent. Neurosci Lett 1985;58:293-297.
89. Newcombe J, Uddin A, Dove R, et al. Glutamate receptor expression in multiple sclerosis lesions. Brain Pathol 2008;18:52-61.
90. Stys PK, Lipton SA. White matter NMDA receptors: an unexpected new therapeutic target? Trends Pharmacol Sci 2007;28:561-566.
91. Wallstrom E, Diener P, Ljungdahl A, et al. Memantine abrogates neurological deficits, but not CNS inflammation, in Lewis rat experimental autoimmune encephalomyelitis. J Neurol Sci 1996;137:89-96.
92. Bolton C, Paul C. MK-801 limits neurovascular dysfunction during experimental allergic encephalomyelitis. J Pharmacol Exp Ther 1997;282:397-402.
93. Smith T, Groom A, Zhu B, et al. Autoimmune encephalomyelitis ameliorated byAMPA antagonists. Nat Med 2000;6:62-66.
94. Groom AJ, Smith T, Turski L. Multiple sclerosis and glutamate. Ann NY Acad Sci 2003;993:229-275.
95. Whitney KD, McNamara JO. GluR3 autoantibodies destroy neural cells in a complement-dependent manner modulated by complement regulatory proteins. J Neurosci 2000;20:7307-7316.
96. Xiong ZQ, Qian W, Suzuki K, et al. Formation of complement membrane attack complex in mammalian cerebral cortex evokes seizures and neurodegeneration. J Neurosci 2003;23:955-960.
97. Mantegazza R, Bernasconi P, Baggi F, et al. Antibodies against GluR3 peptides are not specific for Rasmussen's encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures. J Neuroimmunol 2002;131:179-185.
98. Levite M. Autoimmune epilepsy. Nat Immunol 2003;3:500.
99. Watson R, Jiang Y, Bermudez I, et al. Absence of antibodies to glutamate receptor type 3 (GluR3) in Rasmussen encephalitis. Neurology 2004;63:43-50.
100. Dropcho EJ. Principles of paraneoplastic syndromes. Ann NY Acad Sci 1998;841:246-261.
101. Dalmau J, Tüzün E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007;61:25-36.
102. Iizuka T, Sakai F, Ide T, et al. Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal. Neurology 2008;70:504-511.
103. Storstein A, Knudsen A, Vedeler CA. Proteasome antibodies in paraneoplastic cerebellar degeneration. J Neuroimmunol 2005;165:172-178.
104. Feist E, Dörner T, Kuckelkorn U, et al. Diagnostic importance of antiproteasome antibodies. Int Arch Allergy Immunol 2000;123:92-97.
105. Wright CF, Oswald BW, Dellis S. Vaccinia virus late transcription is activated in vitro by cellular heterogeneous nuclear ribonucleoproteins. J Biol Chem 2001;276:40680-40686.
106. Ducray F, Roos-Weil R, Garcia PY, et al. Devic's syndrome-like phenotype associated with thymoma and anti-CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry 2007;78:325-327.
107. Camdessanché JP, Lassablière F, Meyronnet D, et al. Expression of the onconeural CV2/CRMP5 antigen in thymus and thymoma. J Neuroimmunol 2006;174:168-173.
108. Cross SA, Salomao DR, Parisi JE, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol 2003;54:38-50.
109. Lees F, MacDonald A-M, Turner JWA. Leber's disease with symptoms resembling disseminated sclerosis. J Neurol Neurosurg Psychiatry 1964;27:415-421.
110. Harding AE, Riordan-Eva P, Govan GG. Mitochondrial DNA diseases: genotype and phenotype in Leber's hereditary optic neuropathy. Muscle Nerve 1995;3:S82-S84.
111. Smith PR, Cooper JM, Govan GG, et al. Antibodies to human optic nerve in Leber's hereditary optic neuropathy. J Neurol Sci 1995;130:134-138.
112. Ciric B, Van Keulen V, Paz Soldan M, et al. Antibody-mediated remyelination operates through mechanism independent of immunomodulation. J Neuroimmunol 2004;146:153-161.